Hologic ( (HOLX) ) has released its Q3 earnings. Here is a breakdown of the information Hologic presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hologic, Inc. is a medical technology company that specializes in women’s health, focusing on early detection and treatment through innovative solutions in diagnostics, breast health, and surgical products.
In its third-quarter fiscal 2025 earnings report, Hologic announced revenue of $1,023.8 million, surpassing its guidance, alongside a non-GAAP diluted EPS of $1.08, which also exceeded expectations. The company highlighted a rebound in its Breast Health division and strong performances in other areas.
Key financial metrics revealed a 1.2% increase in revenue compared to the previous year, with diagnostics revenue up by 1.8%, driven by molecular diagnostics. However, Breast Health revenue saw a decline of 5.1% due to lower mammography equipment sales. The company also reported a robust cash flow from operations at $343.2 million and refinanced its credit facilities to enhance financial flexibility.
Looking ahead, Hologic remains optimistic about achieving solid revenue growth in the fourth quarter, with expectations of mid-single-digit growth in organic revenue excluding COVID-19 impacts. The company anticipates that non-GAAP earnings per share will grow faster than revenue, supported by strategic initiatives and operational efficiencies.